Preclinical pharmacology, antitumor activity, and development of pharmacodynamic markers for the novel, potent AKT inhibitor CCT128930
Yap, Timothy A, Walton, Mike I, Hunter, Lisa-Jane K, Valenti, Melanie, de Haven Brandon, Alexis, Eve, Paul D, Ruddle, Ruth, Heaton, Simon P, Henley, Alan, Pickard, Lisa, Vijayaraghavan, Gowri, Caldwell, John J, Thompson, Neil T, Aherne, Wynne, Raynaud, Florence I, Eccles, Suzanne A, Workman, Paul, Collins, Ian, Garrett, Michelle D
Published in Molecular cancer therapeutics (01.02.2011)
Published in Molecular cancer therapeutics (01.02.2011)
Get full text
Journal Article
CCT241533 Is a Potent and Selective Inhibitor of CHK2 that Potentiates the Cytotoxicity of PARP Inhibitors
ANDERSON, Victoria E, WALTON, Michael I, GARRETT, Michelle D, EVE, Paul D, BOXALL, Katherine J, ANTONI, Laurent, CALDWELL, John J, AHERNE, Wynne, PEARL, Laurence H, OLIVER, Antony W, COLLINS, Ian
Published in Cancer research (Chicago, Ill.) (15.01.2011)
Published in Cancer research (Chicago, Ill.) (15.01.2011)
Get full text
Journal Article
CCT244747 Is a Novel Potent and Selective CHK1 Inhibitor with Oral Efficacy Alone and in Combination with Genotoxic Anticancer Drugs
WALTON, Mike I, EVE, Paul D, MATTHEWS, Thomas P, JAMIN, Yann, ROBINSON, Simon P, WYNNEAHERNE, G, READER, John C, CHESLER, Louis, RAYNAUD, Florence I, ECCLES, Suzanne A, COLLINS, Ian, GARRETT, Michelle D, HAYES, Angela, VALENTI, Melanie R, DE HAVEN BRANDON, Alexis K, BOX, Gary, HALLSWORTH, Albert, SMITH, Elizabeth L, BOXALL, Kathy J, LAINCHBURY, Michael
Published in Clinical cancer research (15.10.2012)
Published in Clinical cancer research (15.10.2012)
Get full text
Journal Article
AT13148 Is a Novel, Oral Multi-AGC Kinase Inhibitor with Potent Pharmacodynamic and Antitumor Activity
YAP, Timothy A, WALTON, Mike I, HEINZMANN, Kathrin, JONES, Paul S, FELTELL, Ruth E, REULE, Matthias, WOODHEAD, Steven J, DAVIES, Thomas G, LYONS, John F, RAYNAUD, Florence I, ECCLES, Suzanne A, WORKMAN, Paul, GRIMSHAW, Kyla M, THOMPSON, Neil T, GARRETT, Michelle D, TE POELE, Robert H, EVE, Paul D, VALENTI, Melanie R, DE HAVEN BRANDON, Alexis K, MARTINS, Vanessa, ZETTERLUND, Anna, HEATON, Simon P
Published in Clinical cancer research (15.07.2012)
Published in Clinical cancer research (15.07.2012)
Get full text
Journal Article
Multiparameter Lead Optimization to Give an Oral Checkpoint Kinase 1 (CHK1) Inhibitor Clinical Candidate: (R)‑5-((4-((Morpholin-2-ylmethyl)amino)-5-(trifluoromethyl)pyridin-2-yl)amino)pyrazine-2-carbonitrile (CCT245737)
Osborne, James D, Matthews, Thomas P, McHardy, Tatiana, Proisy, Nicolas, Cheung, Kwai-Ming J, Lainchbury, Michael, Brown, Nathan, Walton, Michael I, Eve, Paul D, Boxall, Katherine J, Hayes, Angela, Henley, Alan T, Valenti, Melanie R, De Haven Brandon, Alexis K, Box, Gary, Jamin, Yann, Robinson, Simon P, Westwood, Isaac M, van Montfort, Rob L. M, Leonard, Philip M, Lamers, Marieke B. A. C, Reader, John C, Aherne, G. Wynne, Raynaud, Florence I, Eccles, Suzanne A, Garrett, Michelle D, Collins, Ian
Published in Journal of medicinal chemistry (09.06.2016)
Published in Journal of medicinal chemistry (09.06.2016)
Get full text
Journal Article
The preclinical pharmacology and therapeutic activity of the novel CHK1 inhibitor SAR-020106
Walton, Michael I, Eve, Paul D, Hayes, Angela, Valenti, Melanie, De Haven Brandon, Alexis, Box, Gary, Boxall, Kathy J, Aherne, G Wynne, Eccles, Suzanne A, Raynaud, Florence I, Williams, David H, Reader, John C, Collins, Ian, Garrett, Michelle D
Published in Molecular cancer therapeutics (01.01.2010)
Published in Molecular cancer therapeutics (01.01.2010)
Get full text
Journal Article
Discovery of 3‑Alkoxyamino-5-(pyridin-2-ylamino)pyrazine-2-carbonitriles as Selective, Orally Bioavailable CHK1 Inhibitors
Lainchbury, Michael, Matthews, Thomas P, McHardy, Tatiana, Boxall, Kathy J, Walton, Michael I, Eve, Paul D, Hayes, Angela, Valenti, Melanie R, de Haven Brandon, Alexis K, Box, Gary, Aherne, G. Wynne, Reader, John C, Raynaud, Florence I, Eccles, Suzanne A, Garrett, Michelle D, Collins, Ian
Published in Journal of medicinal chemistry (26.11.2012)
Published in Journal of medicinal chemistry (26.11.2012)
Get full text
Journal Article
Phosphorylation of cyclin dependent kinase 4 on tyrosine 17 is mediated by Src family kinases
Martin, Nicholas G, McAndrew, Peter C, Eve, Paul D, Garrett, Michelle D
Published in The FEBS journal (01.06.2008)
Published in The FEBS journal (01.06.2008)
Get full text
Journal Article
The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eμ-MYC driven B-cell lymphoma
Walton, Mike I., Eve, Paul D., Hayes, Angela, Henley, Alan T., Valenti, Melanie R., De Haven Brandon, Alexis K., Box, Gary, Boxall, Kathy J., Tall, Matthew, Swales, Karen, Matthews, Thomas P., McHardy, Tatiana, Lainchbury, Michael, Osborne, James, Hunter, Jill E., Perkins, Neil D., Aherne, G. Wynne, Reader, John C., Raynaud, Florence I., Eccles, Suzanne A., Collins, Ian, Garrett, Michelle D.
Published in Oncotarget (19.01.2016)
Published in Oncotarget (19.01.2016)
Get full text
Journal Article
CCT241533 is a potent and selective inhibitor of CHK2 which potentiates the cytotoxicity of PARP inhibitors
Anderson, Victoria E, Walton, Michael I, Eve, Paul D, Boxall, Katherine J, Antoni, Laurent, Caldwell, John J, Pearl, Laurence H, Oliver, Antony W, Collins, Ian, Garrett, Michelle D
Published in Cancer research (Chicago, Ill.) (15.01.2011)
Published in Cancer research (Chicago, Ill.) (15.01.2011)
Get full text
Journal Article
Abstract 928: The novel clinical candidate AT13148 is an oral multi-AGC kinase inhibitor with potent pharmacodynamic and antitumor activity and demonstrates a mechanism of action distinct from AKT inhibitors
Yap, Timothy A., Walton, Michael I., Grimshaw, Kyla M., Poele, Robert H. te, Eve, Paul D., Valenti, Melanie R., de Haven Brandon, Alexis K., Martins, Vanessa, Zetterlund, Anna, Heaton, Simon P., Heinzmann, Kathrin, Jones, Paul S., Feltell, Ruth E., Reule, Matthias, Woodhead, Steven J., Davies, Thomas G., Lyons, John F., Raynaud, Florence I., Eccles, Suzanne A., Workman, Paul, Thompson, Neil T., Garrett, Michelle D.
Published in Cancer research (Chicago, Ill.) (15.04.2012)
Published in Cancer research (Chicago, Ill.) (15.04.2012)
Get full text
Journal Article
Abstract 3503: CCT241533 is a novel, potent and selective inhibitor of CHK2 and potentiates the cellular effects of PARP inhibitors
Anderson, Victoria E., Eve, Paul D., Walton, Michael I., Caldwell, John J., Pearl, Laurence H., Oliver, Antony W., Collins, Ian, Garrett, Michelle D.
Published in Cancer research (Chicago, Ill.) (15.04.2010)
Published in Cancer research (Chicago, Ill.) (15.04.2010)
Get full text
Journal Article
Abstract 3518: Preclinical pharmacology of the novel, potent & selective CHK1 inhibitor SAR-020106
Walton, Michael I., Eve, Paul D., Hayes, Angela, Valenti, Melanie, Brandon, Alexis De Haven, Box, Gary, Aherne, G Wynne, Eccles, Suzanne A., Raynaud, Florence I., Williams, David H., Reader, John C., Collins, Ian, Garrett, Michelle D.
Published in Cancer research (Chicago, Ill.) (15.04.2010)
Published in Cancer research (Chicago, Ill.) (15.04.2010)
Get full text
Journal Article
The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eµ-MYC driven B-cell lymphoma
Walton, Mike I, Eve, Paul D, Hayes, Angela, Henley, Alan T, Valenti, Melanie R, De Haven Brandon, Alexis K, Box, Gary, Boxall, Kathy J, Tall, Matthew, Swales, Karen, Matthews, Thomas P, McHardy, Tatiana, Lainchbury, Michael, Osborne, James, Hunter, Jill E, Perkins, Neil D, Aherne, G Wynne, Reader, John C, Raynaud, Florence I, Eccles, Suzanne A, Collins, Ian, Garrett, Michelle D
Published in Oncotarget (19.01.2016)
Published in Oncotarget (19.01.2016)
Get full text
Journal Article